The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Clinical Features of Advanced Non-Small Cell Lung Cancer in Never-Smokers

비흡연가 폐암의 임상상

  • Jeong, Su-Hyeon (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Jang, Tae-Won (Department of Internal Medicine, Kosin University College of Medicine)
  • 정수현 (고신대학교 의과대학 복음병원 내과) ;
  • 장태원 (고신대학교 의과대학 복음병원 내과)
  • Published : 2011.04.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Smoking is major cause of lung cancer. However, the prevalence of lung cancer in never-smokers increasing recently. This study investigated the clinical characteristics of advanced lung cancer in never-smokers. Methods: We anlyzed the clinical characteristics including demographics, bronchoscopic features, stage, and serum tumor markers, of never smokers with lung cancer seen at Kosin University Hospital from January 2001 to December 2008. Results: There were 105 never smokers with lung cancer (mean age 61 years, 82 females), comprising 83 (79%) adenocarcinomas, 9 (8.6%) squamous carcinomas, and 13 (12.4%) undifferenciated carcinomas. The overall median survival time (MST) was 18.7 months. The MST was longer in females (21.6 vs. 13.7 months, p = 0.03), patients younger than 60 years (19.2 vs. 17.5, p = 0.019), and those with adenocarcinoma (21.6 vs. 8.8 months, p = 0.038), and a neuron-specific enolase level of less than 15 ng/mL (22.4 vs. 13.4 months, p = 0.014). Conclusions: We analyzed the clinical characteristics of advanced lung cancer in never smokers. A more comprehensive study is need to compare never-smokers and smokers with lung cancer and to determine the appropriate treatment for non-smokers.

목적: 본 연구는 비흡연가에서의 진행성 폐암의 임상적 특성에 대해 알고 이를 토대로 적절한 치료 방향 설정하기 위함에 있다 방법: 본원에서 진단된 폐암환자들을 대상으로 의무기록을 통해 105명의 비흡연자를 선별하였으며 수술 가능한 병기의 환자를 제외하고 stage III, IV의 진행 병기 환자를 대상으로 성별, 나이, 신체활동도와 종양 표지자 수치, 생존 기간 등에 대해 조사하였으며 EGFR-TKI 치료반응성에 대해 알아보았다. 결과: 전체 비흡연가 중 여성이 많았고, 조직형상 선암이 많았으며 생존기간의 중앙값은 19.2개월이었으며 여성, 선암, 저연령층, NSE 값이 15이하인 환자들에서 생존기간이 길었다. 또한 EGFR-TKI로 치료받은 군에서 생존기간이 길었으며 관해 지속기간 역시 길게 나타났다. 결론: 비흡연가에서의 폐암 임상상에 대해 알아보았으며 향후 흡연가에서의 임상상과 비교를 통해 비흡연가에 적절한 치료에 대해 연구되어야 한다.

Keywords

References

  1. Korean National Statistical Office. Annual report on the cause of death statistics. Korea National Statistical Office, 2007.
  2. Wynder EL, Graham EA. Landmark article May 27, 1950: tabacco smoking as a possible etiologic factor in bronchogenic carcinoma: A study of six hundred and eighty-four proved cases. JAMA 1985;253:2986-2994. https://doi.org/10.1001/jama.1985.03350440064033
  3. Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. Br Med J 1950;2:739-748. https://doi.org/10.1136/bmj.2.4682.739
  4. Chen CJ, Wu HY, Chuang YC, et al. Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. Anticancer Res 1990;10:971-976.
  5. Koo LC, Ho JH, Lee N. An analysis of some risk factors for lung cancer in Hong Kong. Int J Cancer 1985;35:149-155. https://doi.org/10.1002/ijc.2910350202
  6. Metayer C, Wang Z, Kleinerman RA, et al. Cooking oil fumes and risk of lung cancer in women in rural Gansu, China. Lung Cancer 2002;35:111-117. https://doi.org/10.1016/S0169-5002(01)00412-3
  7. Taioli E, Wynder EL. Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994;86:869-870. https://doi.org/10.1093/jnci/86.11.869
  8. Brenner AV, Wang Z, Kleinerman RA, et al. Menstrual and reproductive factors and risk of lung cancer among Chinese women, eastern Gansu province, 1994-1998. J Epidemiol 2003;13:22-28. https://doi.org/10.2188/jea.13.22
  9. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-2803.
  10. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a Randomised, Placebo-controlled, Multicentre Study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537. https://doi.org/10.1016/S0140-6736(05)67625-8
  11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. https://doi.org/10.1056/NEJMoa050753
  12. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006;24:2245-2251. https://doi.org/10.1200/JCO.2005.04.8033
  13. Brownson RC, Alavanja MC, Caporaso N, Simoes EJ, Chang JC. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev 1998;20:218-236. https://doi.org/10.1093/oxfordjournals.epirev.a017982
  14. Shimizu H, Tominaga S, Nishimura M, Urata A. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. Jpn J Clin Oncol 1984;14:595-600.
  15. Sridhar KS, Raub WA Jr. Present and past smoking history and other predisposing factors in 100 lung cancer patients. Chest 1992;101:19-25. https://doi.org/10.1378/chest.101.1.19
  16. Brownson RC, Loy TS, Ingram E, Mayers JC. Lung cancer in nonsmoking women: Histology and survival patterns. Cancer 1995;75:29-33. https://doi.org/10.1002/1097-0142(19950101)75:1<29::AID-CNCR2820750107>3.0.CO;2-Q
  17. Dutu T, Michiels S, Fouret P, et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 2005;16:1906-1914. https://doi.org/10.1093/annonc/mdi408
  18. Toh CK, Wong EH, Lim WT, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 2004;126:1750-1756. https://doi.org/10.1378/chest.126.6.1750
  19. Maeda T, Ueoka H, Tabata M, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicated poor prognosis. Jpn J Clin Oncol 2000;30:534-541. https://doi.org/10.1093/jjco/hyd139
  20. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001;31:221-231. https://doi.org/10.1016/S0169-5002(00)00186-0
  21. Yesner R, Carter D. Pathology of carcinoma of the lung: changing patterns. Clin Chest Med 1982;3:257-289.
  22. Pujol JL, Simony J, Laurent JC, et al. Bousquet J. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers. Cancer Res 1989;49:2797-2802.
  23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. https://doi.org/10.1056/NEJMoa040938
  24. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. https://doi.org/10.1093/jnci/dji055
  25. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234. https://doi.org/10.1200/JCO.2005.09.985
  26. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54. https://doi.org/10.3904/kjim.2009.24.1.48
  27. Wu JY, Yu CJ, Shin JY, Yang CH, Yang PC. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2010;67:348-354. https://doi.org/10.1016/j.lungcan.2009.04.018
  28. Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010;11:321-330. https://doi.org/10.1016/S1470-2045(10)70042-5